Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid
09 janv. 2017 08h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...